文献速递核素与放射性配体治疗

177Lu、90Y和111In标记的生长抑素受体拮抗剂OPS201与激动剂177Lu-DOTATATE的生物分布、药代动力学和剂量学比较:质量效应

Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect.
PubMed 文献 · J Nucl Med · 2017-04-27

临床前研究比较SSTR2拮抗剂OPS201(分别用177Lu、90Y、111In标记)与激动剂177Lu-DOTATATE,进行生物分布、药代动力学、SPECT/CT和剂量学研究。177Lu-OPS201肿瘤 residence time 为15.6小时(10 pmol),高于177Lu-DOTATATE的6.4小时,4 cm肿瘤剂量0.854 vs 0.333 mGy/MBq。质量递增实验显示拮抗剂无相关肿瘤饱和,增加肽质量可降低有效剂量并改善治疗指数;赖氨酸和琥珀酰明胶可显著降低肾脏剂量。

要点

  • 177Lu-OPS201肿瘤停留时间15.6小时,177Lu-DOTATATE为6.4小时,4 cm肿瘤剂量分别为0.854和0.333 mGy/MBq。
  • 注射10、200和2000 pmol的177Lu-OPS201后4小时肿瘤摄取分别为23.9、24.9和18.8 %IA/g(P>0.05),无相关肿瘤饱和。
  • 肽质量从10增至200 pmol使177Lu-OPS201有效剂量从0.0908降至0.0184 mSv/MBq,并降低肝、骨髓及SSTR2表达器官摄取。

核心结论

  • 与177Lu-DOTATATE和90Y-OPS201相比,177Lu-OPS201具有更高的肿瘤摄取、更长的肿瘤停留时间和改善的肿瘤-肾脏剂量比。
  • 质量递增研究表明,优化的拮抗剂质量可能通过降低肝脏和骨髓剂量以及有效剂量,进一步改善肽受体放射性核素治疗的安全窗。
  • 需要临床研究来确认177Lu-OPS201的疗效和有利的毒性特征。

研究设计与样本

  • 临床前研究,比较SSTR2拮抗剂OPS201(用177Lu、90Y和111In标记)与SSTR2激动剂177Lu-DOTATATE。
  • 进行了生物分布、药代动力学、SPECT/CT和剂量学研究,以评估所有放射性示踪剂的生物等效性。
  • 系统研究了递增肽质量和肾保护剂的使用。

主要发现

  • 177Lu-OPS201(10 pmol)的肿瘤停留时间为15.6小时(13.4-17.7),177Lu-DOTATATE为6.4小时(5.4-7.3);4 cm肿瘤剂量拮抗剂为0.854 mGy/MBq,激动剂为0.333 mGy/MBq,拮抗剂肿瘤剂量高2.5倍。
  • 整体肿瘤-肾脏剂量比,177Lu-OPS201较90Y-OPS201高约24%,较177Lu-DOTATATE高约32%。
  • 111In-OPS201的生物分布与90Y-OPS201显著不同,因此不是90Y-OPS201剂量学研究的替代物。
  • 注射10、200和2000 pmol的177Lu-OPS201后4小时肿瘤摄取分别为23.9、24.9和18.8 %IA/g(P>0.05),未引起相关肿瘤饱和;而177Lu-DOTATATE相应为17.8、12.0和9.9 %IA/g(P<0.05)。
  • 将177Lu-OPS201肽质量从10 pmol增至200 pmol,有效剂量从0.0908降至0.0184 mSv/MBq,并降低肝脏、骨髓和所有SSTR2表达器官的摄取,治疗指数显著改善。

局限性

  • 原文结论指出需要临床研究来确认177Lu-OPS201的疗效和有利的毒性特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiolabeled somatostatin receptor (SSTR) antagonists have shown in vivo higher uptake in SSTR-expressing tumors than agonists. In this preclinical study, the SSTR2 antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]) labeled with 177Lu, 90Y, and 111In was compared with the SSTR2 agonist 177Lu-DOTATATE. Methods: Biodistribution, pharmacokinetics, SPECT/CT, and dosimetry studies were performed to assess the bioequivalence of all radiotracers. Use of escalated peptide mass and nephroprotective agents were systematically investigated. Results: The tumor residence time was 15.6 h (13.4-17.7) for 177Lu-OPS201 (10 pmol) and 6.4 h (5.4-7.3) for 177Lu-DOTATATE, resulting in a 2.5-times-higher tumor dose for the antagonist than for the agonist (0.854 vs. 0.333 mGy/MBq for a 4-cm tumor). The overall tumor-to-kidney dose ratio was approximately 24% and 32% higher for 177Lu-OPS201 than for 90Y-OPS201 and 177Lu-DOTATATE, respectively. 111In-OPS201 had a biodistribution significantly different from 90Y-OPS201 and is therefore not a surrogate for 90Y-OPS201 dosimetry studies. Importantly, and in contrast to 177Lu-DOTATATE, injection of 10, 200, and 2,000 pmol of 177Lu-OPS201 did not cause any relevant tumor saturation, with tumor uptake 4 h after injection: 23.9, 24.9, and 18.8 percentage of injected activity per gram of tissue (%IA/g), respectively, for the antagonist (P > 0.05), as compared with 17.8, 12.0, and 9.9 %IA/g for the agonist (P < 0.05). Increasing the peptide mass of 177Lu-OPS201 from 10 to 200 pmol drastically decreased the effective dose from 0.0908 to 0.0184 mSv/MBq and decreased the uptake in the liver, bone marrow, and all SSTR2-expressing organs; thus, the therapeutic index improved considerably. Lysine and succinylated gelatine, alone or in combination, significantly reduced the renal dose of 177Lu-OPS201 compared with the control group, by 45%, 25%, and 40%, respectively (P < 0.05). The reduction was similar for 10 and 200 pmol, whereas lysine performed better than succinylated gelatine. Conclusion:177Lu-OPS201 exhibits higher tumor uptake, longer tumor residence time, and improved tumor-to-kidney dose ratio compared with 177Lu-DOTATATE and 90Y-OPS201. Importantly, the mass-escalation study indicates that an optimized antagonist mass might further improve the safety window of peptide receptor radionuclide therapy by reducing the liver and bone marrow doses as well as the effective dose. Clinical studies are warranted to confirm the efficacy and advantageous toxicity profile of 177Lu-OPS201.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nicolas GP, Mansi R, McDougall L, et al. Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect. J Nucl Med. 2017. PMID: 28450554. doi:10.2967/jnumed.117.191684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。